FOLR1 and neoplasm: Despite detecting rat anti-human FRα antibodies across all tumour-bearing animals, and rat anti-drug antibodies (ADA) in the serum of one out of ten rats treated with 10 mg/kg and one out of ten rats treated with 50 mg/kg, overall, the study demonstrated that there were no clinical, histopathological or metabolic toxicities [67].